Conv. Plasma
Nigella Sativa

All ibuprofen studies
Meta analysis
study COVID-19 treatment researchIbuprofenIbuprofen (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ ICU admission 52% Improvement Relative Risk Oxygen therapy 52% Hospitalization time 26% Recovery, dyspnea 25% Recovery, fever 43% Recovery, lymphopenia 48% Recovery, cough 41% Ibuprofen  Sobhy et al.  LATE TREATMENT  DB RCT Is late treatment with ibuprofen beneficial for COVID-19? Double-blind RCT 180 patients in Egypt (January - May 2022) Trial compares with acetaminophen, results vs. placebo may differ Lower ICU admission (p=0.047) and lower oxygen therapy (p=0.047) Sobhy et al., The Open Anesthesia J., Apr 2023 Favors ibuprofen Favors acetaminophen

Early Use of Ibuprofen in Moderate Cases of COVID-19 Might be a Promising Agent to Attenuate the Severity of Disease: A Randomized Controlled Trial

Sobhy et al., The Open Anesthesia Journal, doi:10.2174/25896458-v17-e230403-2022-26, PACTR202202880140319
Apr 2023  
  Source   PDF   All   Meta
RCT 180 moderate hospitalized COVID-19 patients in Egypt, showing lower ICU admission and shorter hospitalization with ibuprofen compared with acetaminophen.
Study covers acetaminophen and ibuprofen.
risk of ICU admission, 52.4% lower, RR 0.48, p = 0.047, treatment 10 of 90 (11.1%), control 21 of 90 (23.3%), NNT 8.2.
risk of oxygen therapy, 52.4% lower, RR 0.48, p = 0.047, treatment 10 of 90 (11.1%), control 21 of 90 (23.3%), NNT 8.2.
hospitalization time, 26.3% lower, relative time 0.74, p = 0.01, treatment 90, control 90.
risk of no recovery, 25.0% lower, RR 0.75, p = 1.00, treatment 3 of 90 (3.3%), control 4 of 90 (4.4%), NNT 90, day 4, dyspnea.
risk of no recovery, 42.9% lower, RR 0.57, p = 0.25, treatment 8 of 90 (8.9%), control 14 of 90 (15.6%), NNT 15, day 4, fever.
risk of no recovery, 48.0% lower, RR 0.52, p = 0.04, treatment 13 of 90 (14.4%), control 25 of 90 (27.8%), NNT 7.5, day 4, lymphopenia.
risk of no recovery, 41.2% lower, RR 0.59, p = 0.03, treatment 20 of 90 (22.2%), control 34 of 90 (37.8%), NNT 6.4, day 4, cough.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sobhy et al., 19 Apr 2023, Double Blind Randomized Controlled Trial, Egypt, peer-reviewed, 6 authors, study period January 2022 - May 2022, this trial compares with another treatment - results may be better when compared to placebo, trial PACTR202202880140319. Contact:
This PaperIbuprofenAll
Early Use of Ibuprofen in Moderate Cases of COVID-19 Might be a Promising Agent to Attenuate the Severity of Disease: A Randomized Controlled Trial
Amr Sobhy, Lobna A Saleh, Marwa E L Abdelatty, Marwa E L Abdelatty, Sameh A Refaat, Mohammed Kamal
The Open Anesthesia Journal, doi:10.2174/25896458-v17-e230403-2022-26
Introduction: Critically ill COVID-19 patients undergoing cytokine storm are believed to have a worse prognosis and increased fatality rate. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAIDs) that might prove beneficial for the early management of COVID-19 due to its immunomodulatory effects. This study aimed to assess the efficacy and safety of the early use of ibuprofen to attenuate the severity of the course of COVID-19 and improve outcomes in patients diagnosed with a moderate case of COVID-19 disease. Methods: This randomized, double-blinded prospective study was conducted from January, 2022 to May, 2022, which included a total sample size of 180 patients with moderate cases of COVID-19. The number of patients transferred to intensive care was used as a primary outcome with a proposed large effect size (0.8), alfa =0.05, and power=0.80, so 90 cases were included in each group. Secondary outcomes were inflammatory markers: C-Reactive Protein (CRP), serum ferritin, and interleukin-6 (IL-6), duration of hospital stay, and need for ICU admission. Results: One hundred eighty patients with moderate case of COVID-19 disease were divided in a 1: 1 ratio to receive ibuprofen (IG) or paracetamol (CG). The average age of the included patients was almost 41 years. Statistically significant differences were reported between both groups in terms of improvement in cough symptoms and lymphopenia in IG compared to CG (p= 0.034 and p= 0.044, respectively). Regarding secondary outcomes, statistically, significant differences were reported between the study's groups in terms of the mean number of patients transferred to the ICU in IG compared to the CG (p =0.0.047) and duration of hospitalization (p =0.013), with no significant differences (p > 0.9999) in the occurrence of side effects. Concerning the follow-up of the cytokine storm marker, there was a statistically significant reduction in serum cytokine marker compared to the baseline value (P < 0.05) in the same group. No statistically significant differences were observed when comparing both groups together in terms of serum ferritin level (p =0.570), serum IL-6 level (p =0.580), and CRP level (p =0.401). Conclusion: It can be concluded that early use of ibuprofen as adjuvant therapy in COVID-19 management is effective and safe to attenuate the severity of diseases and improve outcomes.
STANDARDS OF REPORTING CONSORT guidelines and methodology were followed. CONFLICT OF INTEREST The authors declare no conflict of interest, financial or otherwise. SUPPLEMENTARY MATERIALS Supplementary material is available on the Publisher's website.
Bhaskar, Sinha, Banach, Mittoo, Weissert et al., None
Fisman, Shapira, Motro, Pines, Tenenbaum et al., None
Hashimoto, Graham, Geraci, Signaling through the [10] prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness, J Virol
Kelleni, Early use of non-steroidal anti-inflammatory drugs in
Kelleni, Nitazoxanide/azithromycin combination for
Lu, Zhang, Zhan, Preventing mortality in COVID-19
Mirzaei, Karampoor, Sholeh, Moradi, Ranjbar et al., None
Qin, Zhou, Hu, Dysregulation of immune response in
Ramaswamy, Bhargava, Panda, Ostwal, Repurposing, None, Clin Infect Dis, doi:10.1093/cid/ciaa248
Thomas, Non-steroidal anti-inflammatory drug use and outcomes of
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop